NASDAQ: ARCTArcturus Therapeutics Holdings Inc Stock
$8.22+0.19 (+2.37%)
Updated Apr 6, 2026
ARCT Price
$8.22
Fair Value Price
-$5.56
Market Cap
$233.64M
52 Week Low
$5.85
52 Week High
$24.17
P/E
-3.43x
P/B
1.09x
P/S
2.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$82.03M
Earnings
-$65.78M
Gross Margin
100%
Operating Margin
-80.19%
Profit Margin
-80.2%
Debt to Equity
0.27
Operating Cash Flow
-$74M
Beta
1.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ARCT Overview
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARCT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARCT
Ranked#456 of 460
Ranked#456 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $186.85 | A | |
| $23.02 | A | |
| $16.00 | A |
Be the first to know about important ARCT news, forecast changes, insider trades & much more!
ARCT News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARCT ($8.22) is overvalued by 247.83% relative to our estimate of its Fair Value price of -$5.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARCT ($8.22) is not significantly undervalued (247.83%) relative to our estimate of its Fair Value price of -$5.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARCT due diligence checks available for Premium users.
Valuation
ARCT fair value
Fair Value of ARCT stock based on Discounted Cash Flow (DCF)
Price
$8.22
Fair Value
-$5.56
Undervalued by
247.83%
ARCT ($8.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARCT ($8.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
28.11x
Market
30.09x
ARCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
4.75x
ARCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARCT's financial health
Profit margin
Revenue
$7.2M
Net Income
-$29.1M
Profit Margin
-404.1%
ARCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$271.1M
Liabilities
$57.2M
Debt to equity
0.27
ARCT's short-term assets ($241.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARCT's short-term assets ($241.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARCT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.2M
Investing
$88.0k
Financing
$11.7M
ARCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARCT vs Biotech Stocks
Arcturus Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.